Lyra Therapeutics (LYRA) EBIT (2021 - 2025)
Historic EBIT for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$6.2 million.
- Lyra Therapeutics' EBIT rose 4987.14% to -$6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.3 million, marking a year-over-year increase of 6518.14%. This contributed to the annual value of -$96.3 million for FY2024, which is 4354.59% down from last year.
- According to the latest figures from Q3 2025, Lyra Therapeutics' EBIT is -$6.2 million, which was up 4987.14% from -$8.8 million recorded in Q2 2025.
- In the past 5 years, Lyra Therapeutics' EBIT ranged from a high of -$6.2 million in Q3 2025 and a low of -$49.0 million during Q2 2024
- Over the past 5 years, Lyra Therapeutics' median EBIT value was -$13.6 million (recorded in 2021), while the average stood at -$15.1 million.
- As far as peak fluctuations go, Lyra Therapeutics' EBIT plummeted by 19675.82% in 2024, and later skyrocketed by 8197.82% in 2025.
- Quarter analysis of 5 years shows Lyra Therapeutics' EBIT stood at -$13.6 million in 2021, then dropped by 11.12% to -$15.2 million in 2022, then fell by 8.72% to -$16.5 million in 2023, then skyrocketed by 30.76% to -$11.4 million in 2024, then soared by 45.33% to -$6.2 million in 2025.
- Its EBIT stands at -$6.2 million for Q3 2025, versus -$8.8 million for Q2 2025 and -$8.8 million for Q1 2025.